Evidence map›Paper›PMID 41608543›Full record

ArticleIntegrative medicine research2026

Concurrent Chinese and Western medication use and risk of acute exacerbations in chronic obstructive pulmonary disease: A national cohort study.

Ming-Chia Lee, Chih-Yuan Wu, Shih-Ming Chen, Ya-Hui Chang, Tzu-Rong Peng, Jin-Hua Chen, Shoko Satake, Jen-Ai Lee, Chih-Hsin Lee, Jann-Yuan Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Integrative medicine research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ming-Chia LeeDepartment of Pharmacy, New Taipei City Hospital, New Taipei City, Taiwan.
Chih-Yuan WuDepartment of Pharmacy, New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan.
Shih-Ming ChenSchool of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Ya-Hui ChangSchool of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Tzu-Rong PengSchool of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Jin-Hua ChenBiostatistics Center, College of Management, Taipei Medical University, Taipei, Taiwan.
Shoko SatakeCenter for Experimental Pharmacy Practice, Yokohama University of Pharmacy, Yokohama, Japan.
Jen-Ai LeeSchool of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Chih-Hsin LeeDivision of Pulmonary Medicine, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
Jann-Yuan WangDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study examined whether concurrent use of Chinese medications (CMs) and Western medications (WMs) was associated with a reduced risk of acute exacerbation (AE) in patients with chronic obstructive pulmonary disease (COPD). Methods: Using Taiwan's National Health Insurance Research Database (2003-2019), we identified patients aged ≥40 years with COPD receiving specific medications. CM users were matched with nonusers using propensity score matching. The primary outcome was the occurrence of moderate or severe AE within 730 days. Cox proportional hazard models were used to estimate AE risks. Results: A total of 86,510 CM users were matched with 346,034 nonusers. The incidence of AE was lower in the CM users (9.7%) than in the nonusers (10.7%) as was the incidence of severe AE (2.78% vs. 3.79%). Kaplan-Meier analysis showed significantly lower risks of AE in the CM users ( Conclusions: Concurrent CM-WM use is associated with a decreased risk of AE in patients with COPD. Integrating CM into conventional management may offer clinical benefits, though further studies are needed to elucidate the underlying mechanisms.

Indexed as

Acute exacerbationChinese medicationChronic obstructive pulmonary diseaseWestern medication

Identifiers

PMID41608543
PMCPMC12834842

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.